Akari Therapeutics' AKTX-101 Shows Breakthrough Synergy with KRAS Inhibition in Pancreatic Cancer Models
AKTX has more than doubled off its 52-week low of $3.015 on elevated volume (12× avg).
Summary
Akari Therapeutics announced positive preclinical data for its lead drug candidate, AKTX-101, demonstrating synergistic activity with KRAS inhibition in KRAS-mutated pancreatic cancer models. This "breakthrough" finding, featured in an ASCO 2026 abstract, differentiates AKTX-101 from other TROP2 ADCs. This crucial positive pipeline development follows the company's recent Q1 2026 10-Q filing, which included a going concern warning and indicated cash only through June 2026, alongside a highly dilutive private placement. The data offers a potential long-term value driver for the financially distressed company. Akari aims to initiate a Phase 1 clinical trial for AKTX-101 by mid-2027.
At the time of this announcement, AKTX was trading at $7.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $3.02 to $56.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.